01:15 , Jan 12, 2018 |  BC Innovations  |  Product R&D

Avidity’s affinity for muscle

Avidity Biosciences LLC has developed a strategy for delivering siRNA and antisense therapies to tissues outside the liver and has preclinical proof-of-concept for two molecules that target muscle. The company has set its next sights...
01:26 , Jan 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting GALNT14 could help treat breast cancer that metastasizes to the lung. In patients, low primary tumor levels of GALNT14 were associated with lung...
07:00 , Aug 22, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Polypeptide N-acetylgalactosaminyltransferase (GALNT; GalNac-T) Patient sample, cell culture and mouse studies suggest inhibiting GALNT could help treat cancer. Addition of...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Coronary artery disease (CAD) UDP-N-acetyl-a-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GALNT2); protein phosphatase 1 regulatory subunit 3B (PPP1R3B); tetratricopeptide repeat domain 39B (TTC39B) A meta-analysis of...